Seeking Alpha

Colfax Capital is distinctly unimpressed by Oncothyreons (ONTY) development deal with Array....

Colfax Capital is distinctly unimpressed by Oncothyreons (ONTY) development deal with Array. "What a lousy company," Colax tweets. "Now inlicensing other compounds from ARRY while they inlicensed a Bcl last year that is collecting dust." The market is yet to pass its judgement.
Comments (1)
  • Is Colfax Capital Shorting Onty?
    30 May 2013, 03:59 PM Reply Like
DJIA (DIA) S&P 500 (SPY)